CME Group Performance degli utili passati
Criteri Il passato verificati 4/6
CME Group ha registrato una crescita degli utili a un tasso medio annuo di 12.5%, mentre il settore Capital Markets ha registrato utili in crescita a un tasso medio annuo di 6.1%. I ricavi sono stati in crescita a un tasso medio annuo di 8.5%. Il ritorno sul capitale proprio di CME Group è 16% e ha margini netti di 62.9%.
Informazioni chiave
12.55%
Tasso di crescita degli utili
12.46%
Tasso di crescita dell'EPS
| Capital Markets Crescita del settore | 10.26% |
| Tasso di crescita dei ricavi | 8.55% |
| Rendimento del capitale proprio | 16.04% |
| Margine netto | 62.95% |
| Ultimo aggiornamento sugli utili | 31 Mar 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento della narrazione • May 15
CME: Mixed Street Views And New Markets Will Shape Future Earnings Power
Narrative Update on CME Group The analyst price target for CME Group has been trimmed by about $2, reflecting updated views on slightly softer revenue growth and a modestly lower future P/E multiple. At the same time, some analysts highlight areas of support such as commodities volumes as well as agriculture and prediction markets.Aggiornamento della narrazione • Apr 27
CME: Volatile Street Views And New Futures Will Shape Trading Mix
Analysts have nudged their fair value estimate for CME Group down to $308.20 from $311.67, reflecting slightly softer revenue growth assumptions and a higher discount rate, partly balanced by a higher projected profit margin and a modestly lower future P/E, in line with the mix of recent price target trims and increases across the Street. Analyst Commentary Recent Street research on CME Group has been active on both sides, with several firms adjusting price targets and ratings in different directions.Seeking Alpha • Apr 23
CME Group Q1 Earnings Show Strength, But The Stock Still Looks Expensive
Summary CME Group delivered record Q1 volumes and revenue but missed consensus EPS and revenue estimates by narrow margins. CME remains a hold; the stock’s premium valuation already prices in strong volumes, steady cash flows, and its competitive moat. Growth is driven by diverse product expansion, including commodities, crypto, and cross-margining, but near-term upside is limited absent a volatility or trading surge. Key risks are volume normalization, regulatory changes, and tech disruptions; current price fairly reflects both strengths and risks. Read the full article on Seeking AlphaAggiornamento della narrazione • Apr 11
CME: Volatility And New Contracts Will Shape Rare Earths And Crypto Volumes
The updated analyst price target for CME Group has moved higher by about $5 to $311.67. This change reflects analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a marginally higher future P/E multiple, even as they factor in a small trim to projected profit margins.Aggiornamento della narrazione • Mar 26
CME: Volatility And New Contracts Will Shape Rare Earths And Volume Mix
Analysts have made a modest upward adjustment to the CME Group fair value estimate to about $307 from roughly $305, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin, and future P/E following a mix of recent rating changes and price target tweaks across the Street. Analyst Commentary Recent research on CME Group reflects a mixed but generally balanced backdrop, with several firms adjusting ratings and price targets in different directions.Aggiornamento della narrazione • Mar 11
CME: Volatility And New Contracts Will Shape Rare Earths And Clearing Outlook
Our analyst price target for CME Group has moved modestly higher to $305.21 from $299.29, as analysts factor in slightly stronger modeled revenue growth and profitability. This is partially offset by a more conservative future P/E assumption and mixed views on volume drivers across product lines.Aggiornamento della narrazione • Feb 25
CME: Volatility And New Contracts Will Shape Futures And Clearing Outlook
The analyst price target for CME Group edges higher to $232, with recent updates reflecting analysts' focus on firmer commodities volumes, as well as a more expense conscious outlook in their refreshed earnings models. Analyst Commentary Recent Street research around CME Group reflects a mix of optimism on volumes and earnings power, alongside caution on valuation and the cost base.Aggiornamento della narrazione • Feb 10
CME: Volatility And Prediction Markets Will Guide Futures And Clearing Expansion Outlook
The updated analyst price target for CME Group edges higher to about US$297 from roughly US$290, reflecting analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a similar future P/E multiple despite a slightly lower profit margin input. Analyst Commentary Street research on CME Group in recent sessions centers on a cluster of revised price targets and at least one rating change, with several bullish analysts lifting their targets by varying dollar amounts and one major bank fine tuning its view in both directions over a short time frame.Aggiornamento della narrazione • Jan 27
CME: Volatility And Prediction Markets Will Shape Futures Activity Outlook
The analyst price target for CME Group is now US$290.40, a move of about US$2 from the prior US$288.33, as analysts factor in slightly different assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E following mixed recent research that includes both a modest target cut and an upgrade linked to a tilt toward volatility. Analyst Commentary Recent research on CME Group reflects a mix of optimism and caution, with one firm trimming its price target slightly and another upgrading the stock on what it sees as a better setup for volatility related trading activity.Aggiornamento della narrazione • Jan 12
CME: Fee Moat And Prediction Markets Will Shape Futures Activity Outlook
Narrative Update: CME Group CME Group's fair value estimate has edged up by about $1 to roughly $288 per share, as analysts cite the company's strong futures and options moat, a higher price target range of up to $314, and interest in its role within prediction markets as key supports for the updated outlook. Analyst Commentary Recent Street research has been generally constructive on CME Group, with several bullish analysts adjusting their price targets higher and highlighting the company's futures and options franchise as a key support for valuation.Aggiornamento della narrazione • Dec 27
CME: Fee Resilience And Prediction Markets Will Balance Lower Volatility Risks
Analysts have nudged their average price target on CME Group modestly higher, to approximately $287 from about $286, citing the company’s resilient fee-based revenue mix, strong competitive moat in futures and options, and supportive demand signals from prediction market partnerships despite some conflicting views on near term volume volatility. Analyst Commentary Recent Street research presents a mixed but generally constructive view on CME Group, with upward moves in price targets tempered by concerns around volume sensitivity and valuation risk if volatility normalizes.Aggiornamento della narrazione • Dec 13
CME: Fee Resilience And New Prediction Markets Will Help Navigate Volatility
Analysts have raised their fair value estimate for CME Group by about $1 to roughly $286 per share, citing the company’s resilient clearing and transaction fee driven revenue base, modestly higher long term growth expectations, and a reinforced competitive moat highlighted in recent target revisions across the Street. Analyst Commentary Street research on CME Group reflects a wide range of views on valuation and execution, with recent target changes clustering around expectations for resilient fee income but diverging on the sustainability of growth and the impact of lower volatility.Aggiornamento della narrazione • Nov 16
CME: Revenue Resilience And New Ventures Will Balance Volatility Risks Ahead
The average analyst price target for CME Group was raised by approximately $3 to $285, as analysts point to the firm's resilient revenue streams and strong market position amid continued macroeconomic uncertainty. Analyst Commentary Recent analyst activity reflects a mix of optimism and caution regarding CME Group's performance and outlook, particularly as the firm navigates shifting macroeconomic and market conditions.Seeking Alpha • Apr 27
CME: More Market Volatility Equals More Demands - Initiating With Strong Buy
Summary Initiating a 'Strong Buy' rating for CME with a fair value of $301 per share due to increased demand for hedging amid economic uncertainty and market volatility. CME's diverse product offerings and strong trading volume growth, particularly in interest rate options/futures, equity, FX, energy, and commodities, support its robust business model. CME's high operating margin, capex-light business model, and strategic use of Google Cloud enhance profitability and operational efficiency. Key risks include potential pushback on market data price increases and competition from FMX Futures Exchange in the US treasury market. Read the full article on Seeking AlphaSeeking Alpha • Mar 27
CME Group At A New All-Time High - Valuation Concerns Justified?
Summary CME shares have delivered market-beating returns over the past two years, prompting the question of whether it's time to lock in profits. In this update, I discuss whether the rally appears sustainable against the backdrop of the 2024 results published in mid-February. The analysis focuses on average contract volumes and rates, signs of potential underinvestment given the surprisingly strong free cash flow, and includes an update on debt and leverage. I explain why I do not intend to sell my CME stock position despite the elevated valuation, and why I am not even considering a covered call strategy at this time. Read the full article on Seeking AlphaSeeking Alpha • Feb 18
CME Group: High Quality With Good Dividend Yield
Summary CME Group's near-monopoly in futures and options trading, with extraordinary 60% FCF margins, makes it a high-quality, capital-light business despite regulatory costs. Significant acquisitions like CBOT, NYMEX, and KCBT have solidified CME's market dominance, though future focus will be on dividends and smaller acquisitions. CME is slightly undervalued with a 4% dividend yield, making it a strong hold for dividend-focused investors seeking a high-quality business model. Read the full article on Seeking AlphaRipartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come CME Group guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 6,744 | 4,245 | 1,790 | 0 |
| 31 Dec 25 | 6,507 | 4,021 | 1,751 | 0 |
| 30 Sep 25 | 6,385 | 3,717 | 1,695 | 0 |
| 30 Jun 25 | 6,433 | 3,721 | 1,681 | 0 |
| 31 Mar 25 | 6,274 | 3,581 | 1,654 | 0 |
| 31 Dec 24 | 6,120 | 3,482 | 1,646 | 0 |
| 30 Sep 24 | 6,034 | 3,422 | 1,630 | 0 |
| 30 Jun 24 | 5,788 | 3,262 | 1,590 | 0 |
| 31 Mar 24 | 5,616 | 3,157 | 1,577 | 0 |
| 31 Dec 23 | 5,579 | 3,186 | 1,515 | 0 |
| 30 Sep 23 | 5,338 | 3,011 | 1,536 | 0 |
| 30 Jun 23 | 5,228 | 2,942 | 1,519 | 0 |
| 31 Mar 23 | 5,104 | 2,828 | 1,491 | 0 |
| 31 Dec 22 | 5,019 | 2,657 | 1,399 | 0 |
| 30 Sep 22 | 4,833 | 2,633 | 1,443 | 0 |
| 30 Jun 22 | 4,715 | 2,889 | 1,440 | 0 |
| 31 Mar 22 | 4,657 | 2,745 | 1,448 | 0 |
| 31 Dec 21 | 4,690 | 2,617 | 1,418 | 0 |
| 30 Sep 21 | 4,630 | 2,435 | 1,521 | 0 |
| 30 Jun 21 | 4,600 | 1,920 | 1,543 | 0 |
| 31 Mar 21 | 4,603 | 1,913 | 1,564 | 0 |
| 31 Dec 20 | 4,884 | 2,105 | 1,491 | 0 |
| 30 Sep 20 | 4,911 | 2,151 | 1,545 | 0 |
| 30 Jun 20 | 5,109 | 2,375 | 1,539 | 0 |
| 31 Mar 20 | 5,200 | 2,386 | 1,532 | 0 |
| 31 Dec 19 | 4,868 | 2,117 | 1,447 | 0 |
| 30 Sep 19 | 4,959 | 2,033 | 1,518 | 0 |
| 30 Jun 19 | 4,588 | 1,808 | 1,370 | 0 |
| 31 Mar 19 | 4,377 | 1,860 | 1,235 | 0 |
| 31 Dec 18 | 4,309 | 1,962 | 1,126 | 0 |
| 30 Sep 18 | 3,973 | 4,516 | 977 | 0 |
| 30 Jun 18 | 3,959 | 4,413 | 996 | 0 |
| 31 Mar 18 | 3,824 | 4,262 | 993 | 0 |
| 31 Dec 17 | 3,645 | 4,063 | 929 | 0 |
| 30 Sep 17 | 3,658 | 1,498 | 1,014 | 0 |
| 30 Jun 17 | 3,609 | 1,662 | 1,000 | 0 |
| 31 Mar 17 | 3,590 | 1,566 | 1,008 | 0 |
| 31 Dec 16 | 3,595 | 1,534 | 971 | 0 |
| 30 Sep 16 | 3,496 | 1,452 | 984 | 0 |
| 30 Jun 16 | 3,505 | 1,340 | 994 | 0 |
| 31 Mar 16 | 3,418 | 1,284 | 986 | 0 |
| 31 Dec 15 | 3,327 | 1,247 | 985 | 0 |
| 30 Sep 15 | 3,354 | 1,262 | 998 | 0 |
| 30 Jun 15 | 3,266 | 1,192 | 985 | 0 |
Guadagni di qualità: CME ha guadagni di alta qualità.
Margine di profitto in crescita: Gli attuali margini di profitto netti di CME (62.9%) CME sono più alti rispetto allo scorso anno (57.1%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di CME sono cresciuti del 12.5% all'anno negli ultimi 5 anni.
Accelerare la crescita: La crescita degli utili di CME nell'ultimo anno ( 18.5% ) supera la media quinquennale ( 12.5% all'anno).
Guadagni vs Settore: La crescita degli utili CME nell'ultimo anno ( 18.5% ) non ha superato quella del settore Capital Markets 37.2%.
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 16% ) di CME è considerato basso.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 02:53 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
CME Group Inc. è coperta da 34 analisti. 13 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Stephen Biggar | Argus Research Company |
| Benjamin Budish | Barclays |
| Roger Freeman | Barclays |